1. Home
  2. CMTL vs CRDF Comparison

CMTL vs CRDF Comparison

Compare CMTL & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Comtech Telecommunications Corp.

CMTL

Comtech Telecommunications Corp.

HOLD

Current Price

$3.85

Market Cap

109.7M

Sector

Technology

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.68

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMTL
CRDF
Founded
1967
1999
Country
United States
United States
Employees
1385
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
109.7M
130.7M
IPO Year
2024
2012

Fundamental Metrics

Financial Performance
Metric
CMTL
CRDF
Price
$3.85
$1.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$6.00
$9.63
AVG Volume (30 Days)
171.2K
615.8K
Earning Date
06-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
N/A
N/A
Revenue
$499,528,000.00
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.61
52 Week Low
$1.71
$1.48
52 Week High
$6.21
$4.56

Technical Indicators

Market Signals
Indicator
CMTL
CRDF
Relative Strength Index (RSI) 49.27 49.62
Support Level $2.78 $1.51
Resistance Level $4.24 $1.68
Average True Range (ATR) 0.21 0.08
MACD 0.03 0.01
Stochastic Oscillator 64.66 50.00

Price Performance

Historical Comparison
CMTL
CRDF

About CMTL Comtech Telecommunications Corp.

Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: